Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 129, Issue 6, Pages 912-917Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/CP3HGX7H753QQU8T
Keywords
endometrial endometrioid adenocarcinorna; pathologic features; lymphovascular invasion; prognosis; distant recurrence; adjuvant therapy
Categories
Ask authors/readers for more resources
To evaluate the value of lymphovascular invasion (LVI) in endometrial endometrioid adenocarcinoma (EEA) as a predictor for distant recurrence, we analyzed the histopathologic features of 513 consecutive cases of nonsurgically staged EEA limited to the uterus. Grade, myoinvasion, cervical involvement, and LVI were evaluated. With a median follow-up of 28 months (range, 2-144 months), 67 cases (13.1%) recurred, 37 (7.2%) had locoregional recurrence, and 30 (5.8%) developed distant recurrence. LVI was identified in 116 cases (22.6%) cases and was the only adverse histopathologic finding in 23 cases; 5 (22%) of the 23 recurred. Multivariate analysis demonstrated a significant association between any type of recurrence and cervical involvement (hazard ratio [HR], 2.760; 95% confidence interval [CI], 1.621-4.698) and LVI (HR, 2.717; CI, 1.568-4.707). Multivariate analysis revealed LVI as the only independent predictor for distant recurrence (HR, 2.841; CI, 1.282-6297). Studies to examine the role of adjuvant systemic therapy inpatients with early-stage disease should be considered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available